Background: Antimicrobial Resistance (AMR) and Tuberculosis (TB) are global
concern. According to the WHO fact sheet on tuberculosis, in 2017, 10 million people fell ill with
TB, and 1.6 million including 230,000 children died from the disease. There is a critical need of
design and development of novel chemotherapeutic agents to combat the emergence and increasing
prevalence of resistant pathogens. In the present study, a new series of 1,3,4-oxadiazoles
incorporating benzimidazole and pyridine scaffolds in a single molecular framework has been
Methods: The structures of the synthesized derivatives (4a to 4e) were assigned by IR, NMR and
mass spectral techniques. The hybrid compounds were evaluated for their antimicrobial,
antitubercular and antioxidant activities. In addition, docking simulations were performed to study
ligand-protein interactions and to determine the probable binding conformations.
Results: Molecule 4a has shown anti-tubular activities with MIC 1.6 μg/ml. As compared to
ascorbic acid activities (IC50 = 62.91 μg/ml), molecule 4e exhibited better antioxidant activities
(IC50 = 24.85 μg/ml). Also, molecule 4e has shown significant antimicrobial activities.
Conclusion: The synthesized derivatives from 4a to 4e have exhibited various medicinal activities
and could be emerged as lead compounds and further explored as potential therapeutic agents.